DIGISTAIN® – Risk profiling test for hormone receptor-positive breast cancer.
Digistain is a rapid personalised breast cancer treatment Decision Making. This innovation from the UK, provides much faster breast cancer treatment. It provides the best decision-making data to physicians, reducing time to treatment and enabling personalised critical care. It helps find the best course of treatment and whether cytotoxic therapy in addition to hormone therapy is required.
This clinical aid is best in class predictive power with clinical evidence equivalent to leading NICE approved tumour profiling tests. It also significantly lowers cost per biopsy test than first-generation risk scoring providers.
Quick, clear, actionable data
Delivering radically faster breast cancer treatment decision-making for physicians and patients – reducing actionable treatment decision times from months and weeks to < 1 hour